Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: rationale and design of the STRENGTH trial

Nicholls, Stephen J., Lincoff, A. Michael, Bash, Dianna, Ballantyne, Christie M., Barter, Philip J., Davidson, Michael H., Kastelein, John J. P., Koenig, Wolfgang +9 more·2018·Clinical Cardiology
DOI 10.1002/clc.23055

Cited by (168)

Items 101–168 of 168

  1. Dietary Reference Intakes based on chronic disease endpoints: outcomes from a case study workshop for omega 3’s EPA and DHA
    Megan Racey, Amanda J MacFarlane, Susan E. Carlson, Ken D. Stark, Mélanie Plourde, Catherine J. Field, Allison A. Yates, George A. Wells, Andrea Grantham, Richard Paul Bazinet et al. · 2021 · Applied Physiology, Nutrition, and Metabolism
  2. Icosapent Ethyl: Niche Drug or for the Masses?
    Najdat Bazarbashi, Michael J. Miller · 2020 · Current Cardiology Reports
  3. Oxidized Lipids and Lipoprotein Dysfunction in Psoriasis
    Alexander V. Sorokin, Alan Thomas Remaley, Nehal N. Mehta · 2020 · Journal of Psoriasis and Psoriatic Arthritis
  4. Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE)
    Andrew P. Ambrosy, Umar I. Malik, Rachel C. Thomas, Rishi Parikh, Thida C. Tan, Choon Hwa Goh, Van N. Selby, Matthew D. Solomon, Harshith Reddy Avula, Jesse K. Fitzpatrick et al. · 2021 · American Heart Journal
  5. Omega n-3 Supplementation: Exploring the Cardiovascular Benefits Beyond Lipoprotein Reduction
    Alberto Zambon, Angela Pirillo, Sabina Zambon, Giuseppe Danilo Norata, Alberico Luigi Catapano · 2020 · Current Atherosclerosis Reports
  6. Icosapent ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol
    Najdat Bazarbashi, Michael J. Miller · 2020 · Expert Review of Cardiovascular Therapy
  7. When to lower triglycerides?
    Om P. Ganda · 2020 · Current Opinion in Lipidology
  8. Omega-3FAs Can Inhibit the Inflammation and Insulin Resistance of Adipose Tissue Caused by HHcy Induced Lipids Profile Changing in Mice
    Jing Li, Heng Zhang, Yongqiang Dong, Xian Wang, Guang Wang · 2021 · Frontiers in Physiology
  9. Dyslipidemia in Diabetes
    Kenneth R. Feingold · 2020 · Europe PMC (PubMed Central)
  10. Effects of mineral oil administration on the pharmacokinetics, metabolism and pharmacodynamics of atorvastatin and pravastatin in mice and dogs
    V. Sashi Gopaul, Elsbet Jantine Pieterman, Hans M. G. Princen, Linnéa Bergenholm, Eva Lundborg, Anders Cavallin, Magnus J. Johansson, Glen Hawthorne, Anders Björkbom, Maria Hammarberg et al. · 2021 · European Journal of Pharmaceutical Sciences
  11. A New Beginning for Triglyceride-Lowering Therapies
    Aruna D. Pradhan · 2019 · Circulation
  12. Icosapent Ethyl for Hypertriglyceridemia: Insights From the REDUCE-IT Trial
    Michael J. Miller · 2019 · Future Cardiology
  13. Reducing Cardiovascular Disease Risk in Women Beyond Statin Therapy: New Insights 2020
    Lori J. Mosca, Ann Marie Návar, NANETTE KASS WENGER · 2020 · Journal of Women s Health
  14. Omega-3 fatty acid exposure with a low-fat diet in patients with past hypertriglyceridemia-induced acute pancreatitis; an exploratory, randomized, open-label crossover study
    Richard L. Dunbar, Daniel Gaudet, Michael H. Davidson, Martin Rensfeldt, Hong Yang, Catarina A.M. Nilsson, Mats Kvarnström, Jan Oscarsson · 2020 · Lipids in Health and Disease
  15. Risk of Total Events With Icosapent Ethyl
    Granger, Christopher B., Nelson, Adam J., Pagidipati, Neha J. · 2019 · Journal of the American College of Cardiology
  16. Remnant Cholesterol: Quantification, Concentrations by Sex and Age, and Risk of Ischemic Heart Disease
    Mie Balling, Shoaib Afzal, Anette Varbo, Børge Grønne Nordestgaard, Anne Langsted · 2024 · Clinical Chemistry
  17. Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides
    Manan Pareek, Richard Preston Mason, Deepak L. Bhatt · 2021 · Expert Opinion on Drug Safety
  18. The Rise and Fall “ing” of the HDL Hypothesis
    Julien Feghaly, Arshag D. Mooradian · 2020 · Drugs
  19. The fish-oil paradox
    Stephen James Nicholls, Adam J. Nelson · 2020 · Current Opinion in Lipidology
  20. Cardiovascular Disease Risk Reduction in Mild-Moderate Hypertriglyceridemia: Integrating Prescription of Omega-3 with Standard Treatment
    Fabien A. Picard, Philippe Gabríel Steg · 2021 · Current Atherosclerosis Reports
  21. Marine-derived n-3 fatty acids therapy for stroke
    Celia Gabriela Alvarez Campano, Mary Joan MacLeod, Lorna S. Aucott, Frank Thiès · 2019 · Cochrane Database of Systematic Reviews
  22. The return of triglycerides and revival of omega-3 fatty acids!
    Jean Ferrières · 2020 · Archives of cardiovascular diseases
  23. The Truth About Fish (Oil) in the Treatment of Dyslipidemia
    Jan V Pitha, R. Poledne · 2021 · Current Atherosclerosis Reports
  24. What is new in lipid‐lowering therapies in diabetes?
    Yee-Ming Melody Cheung, Richard O’Brien, Elif Ilhan Ekinci · 2019 · Internal Medicine Journal
  25. Emerging Strategies for the Management of Atherogenic Dyslipidaemia
    Anandita Agarwala, Michael David Shapiro · 2020 · European Cardiology Review
  26. Marine-derived n-3 fatty acids therapy for stroke
    Celia Gabriela Alvarez Campano, Mary Joan MacLeod, Lorna S. Aucott, Frank Thiès · 2022 · Cochrane Database of Systematic Reviews
  27. Omega-3 fatty acid therapy for cardiovascular disease: justified or not?
    Kevin Carl Maki, Mary R. Dicklin · 2020 · Current Opinion in Cardiology
  28. Fatty acids
    Rubén Agregán, Teodora Lyudmilova Popova, María López‐Pedrouso, J. Cantalapiedra, José Manuel Lorenzo, Daniel Franco · 2022 · Elsevier eBooks
  29. Differential cardiovascular impact of ω-3 fatty acid in patients at high cardiovascular risk in Asians versus non-Asians: Sub-analysis of the strength randomized clinical trial
    Tom Kai Ming Wang, Stephen James Nicholls, Julie St. John, Kathy Wolski, Steven E. Nissen · 2025 · Atherosclerosis
  30. Pathophysiology and Management of Dyslipidemias Associated with Insulin-Resistant States
    Kevin Carl Maki, Lane B. Benes, Mary R. Dicklin · 2020 · Contemporary cardiology
  31. The Novelty of Icosapent Ethyl in the Management of Hypertriglyceridemia and Alleviating Cardiovascular Risk
    Muhammad Shoaib Khan, Muhammad Ishaq, Muhammad Talha Ayub, Ateeq U. Rehman, John J. Hayes, M. Eyman Mortada, Robert W Biederman · 2021 · Journal of Lipids
  32. Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies
    Alam, Usman, Mathai, Sheetal V., Filtz, Annalisa, Kuno, Toshiki, Badimon, Juan J., Sniderman, Allan D., Virani, Salim S., Toth, Peter P., Shapiro, Michael D., Lavie, Carl J. et al. · 2026 · Current Cardiology Reports
  33. Temporal decline in non–high-density lipoprotein cholesterol in subjects with diabetes mellitus without atherosclerotic cardiovascular disease
    Gloria Lena Vega, Jijia Wang, Scott M. Grundy · 2020 · Journal of clinical lipidology
  34. Current state-of-the-art knowledge on the role of omega-3 fatty acids in the prevention of cardiovascular disease
    Longina Kłosiewicz−Latoszek, Barbara Cybulska, Piotr Zbigniew Tyszko · 2020 · Annals of Agricultural and Environmental Medicine
  35. Treatment of Hypertriglyceridemia: A Review of Therapies in the Pipeline
    Jiashan Xu, Emily J. Ashjian · 2021 · Journal of Pharmacy Practice
  36. Chylomicronemia through a burr hole: A case report
    Wann Jia Loh, Ramesh Bakthavachalam, Tavintharan Subramaniam, Sharon Li Ting Pek, Fionn Chua, Lester Lee, Gerald Francis Watts · 2022 · Frontiers in Cardiovascular Medicine
  37. Investigational drugs in development for hypertriglyceridemia: a coming-of-age story
    David Rhainds, Mathieu R. Brodeur, Jean‐Claude Tardif · 2019 · Expert Opinion on Investigational Drugs
  38. Role of Glucose and Lipids in the Atherosclerotic Cardiovascular Disease of Patients with Diabetes
    Kenneth R. Feingold · 2020 · Europe PMC (PubMed Central)
  39. Pharmacokinetics of Single and Multiple Doses of Omega‐3 Carboxylic Acids in Healthy Chinese Subjects: A Phase I, Open‐Label Study
    Shan Jing, Zhenxian Zhang, Xiaowen Chen, Rui Miao, Catarina A.M. Nilsson, Lin Yang · 2020 · Clinical Pharmacology in Drug Development
  40. Modified Lipids as Functional Ingredients for Chronic Disease Management
    Emily Amenyenu, Queen S. Abbah, Abosede O. Fawole, John Oloche Onuh · 2025 · Journal of Food Science
  41. The effectiveness of intervention with omega-3 fatty acids, eicosapentaenoic and docosahexenoic acid in peripheral arterial disease: a systematic review and meta-analysis
    Thi K. Dao, Nitesh Nerlekar, Stephen James Nicholls, Kristen J. Bubb · 2025 · Nutrition Metabolism and Cardiovascular Diseases
  42. Trials in “True” Dyslipidemic Patients Are Urged to Reconsider Comprehensive Lipid Management as a Means to Reduce Residual Cardiovascular Risk
    José Pablo Werba, Lorenzo Vigo, Fabrizio Veglia, Giancarlo Marenzi, Elena Tremoli, Damiano Baldassarre · 2019 · Clinical Pharmacology & Therapeutics
  43. Optimal Non-invasive Strategies to Reduce Recurrent Atherosclerotic Cardiovascular Disease Risk
    Maeve Jones‐O’Connor, Pradeep Natarajan · 2019 · Current Treatment Options in Cardiovascular Medicine
  44. Chronic Oral Administration of Mineral Oil Compared With Corn Oil: Effects on Gut Permeability and Plasma Inflammatory and Lipid Biomarkers
    Elsbet Jantine Pieterman, Hans M. G. Princen, Annica Jarke, Ralf G. Nilsson, Anders Cavallin, Linnéa Bergenholm, Marcus Henricsson, V. Sashi Gopaul, Rahul Agrawal, Steven E. Nissen et al. · 2021 · Frontiers in Pharmacology
  45. Triglyceride-rich Lipoprotein Cholesterol (Remnant Cholesterol) as a Therapeutic Target for Cardiovascular Disease Risk
    Børge Grønne Nordestgaard, Anette Varbo · 2020 · Contemporary cardiology
  46. Hydroxytyrosyl Eicosapentaenoate as a Potential Antioxidant for Omega-3 Fatty Acids: Improved Synthesis and Comparative Evaluation with Other Natural Antioxidants
    Natalia García-Acosta, Rosa Cert, Marta Jordán, Luis Goya, Raquel Mateos, Jose Luis Espartero · 2025 · Biomolecules
  47. The time for lipoprotein(a) based intervention has arrived: where will the light shine?
    Stephen James Nicholls, Adam J. Nelson · 2019 · Journal of Thoracic Disease
  48. Translating plasma eicosapentaenoic acid concentrations into erythrocyte percentages of eicosapentaenoic acid plus docosahexaenoic acid during treatment with icosapent ethyl
    William Stephen Harris, Kristina Harris Jackson · 2019 · Journal of clinical lipidology
  49. A Look Beyond Statins and Ezetimibe: a Review of Other Lipid-Lowering Treatments for Cardiovascular Disease Prevention in High-Risk Patients
    Pierre François Sabouret, Denis Angoulvant, Atul Pathak, Francesco Costa, Théo Pezel, Erin D. Michos · 2019 · Current Cardiovascular Risk Reports
  50. Current and future trends in the treatment of dyslipidemias
    Michal Vrablı́k · 2019 · Vnitřní lékařství
  51. Hypertriglyceridaemia: Contemporary management of a neglected cardiovascular risk factor
    Tina Z. Khan, Ulrike Schatz, Stefan Richard Bornstein, Mahmoud Barbir · 2021 · Global Cardiology Science and Practice
  52. Hypertriglyceridaemia and its multifaceted mechanisms driving atherosclerotic cardiovascular disease
    Xintong Li, Lishuang Xu, Li J, Yong Luo, Hang Shen, Daqing Zhang · 2026 · Lipids in Health and Disease
  53. Translating Evidence From Clinical Trials of omega-3 Fatty Acids to Clinical Practice
    Adam J. Nelson, Stephen James Nicholls · 2020 · Future Cardiology
  54. Current and Emerging Therapies for Atherosclerosis
    Adam J. Nelson, Stephen James Nicholls · 2020 · Springer eBooks
  55. Management of Hypertriglyceridemia (Including Fibrates and n-3 Fatty Acids)
    Matthew C. Evans, Michael J. Miller · 2020 · Contemporary cardiology
  56. Secondary Prevention of Atherosclerotic Cardiovascular Disease
    David Power, Robert S. Rosenson · 2022 · Interventional Cardiology
  57. Navigating omega-3s
    Orly P. Ran Sapir, Stephen Louis Kopecky, Francisco Alejandro López-Jiménez · 2024 · European Journal of Preventive Cardiology
  58. Prevention is back in the spotlight – Highlights from American Heart Association Scientific Sessions 2018
    Konstantin Alexander Krychtiuk, Walter Stefan Speidl · 2018 · European Journal of Preventive Cardiology
  59. High-Dose Omega-3 Fatty Acids in Cardiovascular Prevention: Finally Living Up to Their Potential?
    Adam J. Nelson, Sam Mirzaee, Stephen James Nicholls · 2019 · American Journal of Cardiovascular Drugs
  60. 6. Update for the Management of Dyslipidemia
    Koutaro Yokote · 2019 · Nihon Naika Gakkai Zasshi
  61. Impact of Dyslipidemia on Ischemic Stroke
    Yong‐Jae Kim, Eung Gyu Kim · 2021 · Stroke revisited
  62. Eicosapentaenoic Acid Based Therapies: Fish Facts and Stories
    Aravind Reddy Kuchkuntla, Sri Harsha Patllola, Tamim I. Rajjo · 2021 · Journal of Medicine and HealthCare
  63. 6. Update for the Management of Dyslipidemia
    Koutaro Yokote · 2019 · Nihon Naika Gakkai Zasshi
  64. Icosapent Ethyl for the Prevention of Cardiovascular Events
    Jenny Lloyd · 2019 · EMJ Cardiology
  65. Diagnostik und Therapie von Hyperlipidämien bei Kindern und Jugendlichen
    Johannes F. W. Weigel, Karl Otfried Schwab · 2024 · Kinder- und Jugendmedizin
  66. Additional file 1 of Omega-3 fatty acid exposure with a low-fat diet in patients with past hypertriglyceridemia-induced acute pancreatitis; an exploratory, randomized, open-label crossover study
    Richard L. Dunbar, Daniel Gaudet, Davidson, Michael, Martin Rensfeldt, Yang, Hong, Catarina A.M. Nilsson, Mats Kvarnström, Oscarsson, Jan · 2020 · Figshare
  67. Dietary patterns, nutrition, and food–drug interactions during statin therapy: a narrative review
    M.J. Mazur, Rafal Lenard, Seda Önal, Joanna Popiołek-Kalisz · 2026 · Global Perspectives on Nutrition
  68. BindingDB Entry 50018508: Application of marine natural products in drug research.
    BindingDB · 2024 · UC San Diego